Linked Life Data

14722890

Source:http://linkedlifedata.com/resource/pubmed/id/14722890

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14722890rdf:typepubmed:Citationlld:pubmed
pubmed-article:14722890lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:14722890lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:14722890lifeskim:mentionsumls-concept:C0443315lld:lifeskim
pubmed-article:14722890lifeskim:mentionsumls-concept:C0020967lld:lifeskim
pubmed-article:14722890lifeskim:mentionsumls-concept:C0178539lld:lifeskim
pubmed-article:14722890lifeskim:mentionsumls-concept:C0025010lld:lifeskim
pubmed-article:14722890lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:14722890lifeskim:mentionsumls-concept:C1112870lld:lifeskim
pubmed-article:14722890lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:14722890lifeskim:mentionsumls-concept:C0205225lld:lifeskim
pubmed-article:14722890pubmed:issue2lld:pubmed
pubmed-article:14722890pubmed:dateCreated2004-1-14lld:pubmed
pubmed-article:14722890pubmed:abstractTextInfants were immunized by aerosol (10(3.6) plaque-forming units [pfu]/dose) or subcutaneous (sc) (10(4.27) pfu/dose) administration of Edmonston-Zagreb measles vaccine. Measles-specific T cell proliferative responses with a stimulation index of > or =3 developed in 72% of children given aerosol-administered vaccine, compared with 87% given s.c.-administered vaccine (P =.06). Seroconversion rates were 90% after aerosol-administered vaccine and 100% after s.c.-administered vaccine (P=.01), and measles geometric mean titers were 237 milli-international units (mIU) (95% confidence interval [CI], 146-385 mIU) and 487 mIU (95% CI, 390-609 mIU) in each group, respectively (P=.01). Measles-specific T and B cell responses were weaker after aerosol than after sc vaccination, indicating a need to use a higher aerosol dose to achieve optimal immunogenicity.lld:pubmed
pubmed-article:14722890pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14722890pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14722890pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14722890pubmed:languageenglld:pubmed
pubmed-article:14722890pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14722890pubmed:citationSubsetAIMlld:pubmed
pubmed-article:14722890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14722890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14722890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14722890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14722890pubmed:statusMEDLINElld:pubmed
pubmed-article:14722890pubmed:monthJanlld:pubmed
pubmed-article:14722890pubmed:issn0022-1899lld:pubmed
pubmed-article:14722890pubmed:authorpubmed-author:Valdespino-Gó...lld:pubmed
pubmed-article:14722890pubmed:authorpubmed-author:García-García...lld:pubmed
pubmed-article:14722890pubmed:authorpubmed-author:Islas-RomeroR...lld:pubmed
pubmed-article:14722890pubmed:authorpubmed-author:ArvinAnn MAMlld:pubmed
pubmed-article:14722890pubmed:authorpubmed-author:MaldonadoYvon...lld:pubmed
pubmed-article:14722890pubmed:authorpubmed-author:BeelerJudy...lld:pubmed
pubmed-article:14722890pubmed:authorpubmed-author:AudetSusetteSlld:pubmed
pubmed-article:14722890pubmed:authorpubmed-author:GansHayleyHlld:pubmed
pubmed-article:14722890pubmed:authorpubmed-author:Wong-ChewRosa...lld:pubmed
pubmed-article:14722890pubmed:authorpubmed-author:Santos-Precia...lld:pubmed
pubmed-article:14722890pubmed:authorpubmed-author:Lew-YasukawaL...lld:pubmed
pubmed-article:14722890pubmed:issnTypePrintlld:pubmed
pubmed-article:14722890pubmed:day15lld:pubmed
pubmed-article:14722890pubmed:volume189lld:pubmed
pubmed-article:14722890pubmed:ownerNLMlld:pubmed
pubmed-article:14722890pubmed:authorsCompleteYlld:pubmed
pubmed-article:14722890pubmed:pagination254-7lld:pubmed
pubmed-article:14722890pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:14722890pubmed:meshHeadingpubmed-meshheading:14722890...lld:pubmed
pubmed-article:14722890pubmed:meshHeadingpubmed-meshheading:14722890...lld:pubmed
pubmed-article:14722890pubmed:meshHeadingpubmed-meshheading:14722890...lld:pubmed
pubmed-article:14722890pubmed:meshHeadingpubmed-meshheading:14722890...lld:pubmed
pubmed-article:14722890pubmed:meshHeadingpubmed-meshheading:14722890...lld:pubmed
pubmed-article:14722890pubmed:meshHeadingpubmed-meshheading:14722890...lld:pubmed
pubmed-article:14722890pubmed:meshHeadingpubmed-meshheading:14722890...lld:pubmed
pubmed-article:14722890pubmed:meshHeadingpubmed-meshheading:14722890...lld:pubmed
pubmed-article:14722890pubmed:meshHeadingpubmed-meshheading:14722890...lld:pubmed
pubmed-article:14722890pubmed:meshHeadingpubmed-meshheading:14722890...lld:pubmed
pubmed-article:14722890pubmed:meshHeadingpubmed-meshheading:14722890...lld:pubmed
pubmed-article:14722890pubmed:meshHeadingpubmed-meshheading:14722890...lld:pubmed
pubmed-article:14722890pubmed:year2004lld:pubmed
pubmed-article:14722890pubmed:articleTitleInduction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children.lld:pubmed
pubmed-article:14722890pubmed:affiliationDept. de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico. rmwong@correo.unam.mxlld:pubmed
pubmed-article:14722890pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14722890pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:14722890pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:14722890pubmed:publicationTypeRandomized Controlled Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14722890lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14722890lld:pubmed